Why Greece Works for Biotech / Life Sciences
Funding access (85/100) is a standout for Greece Biotech / Life Sciences companies. The local market has 16 active VC funds, with average seed checks of $500K. Government grant programs include Research - Innovate 2021-2027 (ESPA/NSRF) ($325K) and ESPA Support for New SME Establishment ($440K). Non-dilutive capital availability reduces the pressure to give up equity at early stage, which is particularly valuable for capital-efficient Biotech / Life Sciences businesses.
Family viability (85/100) is a genuine strength for Greece - important for Biotech / Life Sciences founders relocating with a partner or children. The cost of living index is 40 (NYC = 100), with a comfortable family monthly budget of $4K. Safety scores 54/100. International schools are available, and healthcare quality scores 59/100 with private insurance running approximately $540/month.
Operational ease (83/100) makes Greece practical for Biotech / Life Sciences founders setting up from scratch. Banking difficulty for foreigners is rated moderate. Company formation takes approximately 10 days at a cost of around $2K, with annual compliance costs around $3K. Full foreign ownership is permitted - no local partner required. IP protection quality is rated moderate, which matters for Biotech / Life Sciences businesses with proprietary technology or brand assets.